June 1, 2017 Tumor Mutational Burden (TMB): Assessment of inter-and intra-tumor heterogeneity Read more »
July 31, 2020 Economic burden of checkpoint inhibitor immunotherapy for the treatment of non-small cell lung cancer in U.S. clinical practice Read more »
June 20, 2020 Tumor inflammatory signature as a biomarker of response to immunotherapy in lung cancer Read more »
September 1, 2021 Diverse RNA expression patterns of T cell priming markers in various solid tumors and their clinical implication Read more »
September 1, 2021 Cancer/testis antigen expression landscape in gastroesophageal adenocarcinoma Read more »
September 30, 2021 Aligning Tumor Mutational Burden (TMB) quantification across diagnostic platforms: Phase 2 of the Friends of Cancer Research TMB Harmonization Project Read more »
November 1, 2021 Molecular profiling of metastatic renal cell carcinoma treated with ipilimumab-nivolumab Read more »
April 2, 2022 Cancer testis antigen burden: pan-cancer distribution and survival implications Read more »
March 4, 2021 T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors Read more »
